Open AccessJournal Article
[Molecular-targeted therapy for malignant glioma].
TLDR
The development of the main molecular targeted non-cytotoxic agents investigated in glioma are reviewed, highlighting lessons derived from the development of these novel drugs and proposing new horizons for the clinical development of molecular-targeted therapies.Abstract:
Over the past decade, molecular-targeted therapies have been added to cytotoxic and anti-endocrine drugs in the treatment of cancer, with an aim to target the molecular pathways underlying the carcinogenic processes and maintaining cancer phenotypes. Success with some of these agents has suggested that identification and validation of the drug target is the starting point to the route of development of active, safe, and effective drugs. The main molecular targets employed for the development of anticancer drugs are cell surface receptors, signal transduction pathways, gene transcription targets, ubiquitin-proteasome/heat shock proteins, and tumor microenvironment components (especially, antiangiogenic agents). In this paper, we review the development of the main molecular targeted non-cytotoxic agents investigated in glioma, highlighting lessons derived from the development of these novel drugs and proposing new horizons for the clinical development of molecular-targeted therapies.read more
Citations
More filters
Journal ArticleDOI
Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study.
Michel Wager,Philippe Menei,Joelle Guilhot,Pierre Levillain,Sophie Michalak,B. Bataille,J.-L. Blanc,F. Lapierre,Philippe Rigoard,Serge Milin,F. Duthe,Dominique Bonneau,C.J. Larsen,Lucie Karayan-Tapon +13 more
TL;DR: P14ARF, p16INK4A and PTEN expressions, and hTERT expression for high-grade tumours, EGFR for glioblastomas, 10q26 LOH for grade III tumours and anaplastic oligodendrogliomas were found to be correlated with overall survival on univariate analysis and age and grade on multivariate analysis only.
Journal ArticleDOI
Tetrandrine suppresses human glioma growth by inhibiting cell survival, proliferation and tumour angiogenesis through attenuating STAT3 phosphorylation.
Ji-Wei Ma,Yong Zhang,Ru Li,Jiecheng Ye,Hai-Ying Li,Yikai Zhang,Zheng-lai Ma,Jin-ying Li,Xueyun Zhong,Xuesong Yang +9 more
TL;DR: The data indicate that STAT3 is involved in Tet-induced the regression of glioma growth by activating tumour cell apoptosis, inhibitingglioma cell proliferation and inhibiting angiogenesis.
Journal ArticleDOI
Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma.
TL;DR: Evidence is summarized that EMT may precipitate GBM resistance to EGFR-targeted therapy, and may thus be among the principal factors contributing to the clinical failure of targeted therapy against EGFR and EGFRvIII.
Journal ArticleDOI
TRIM22 orchestrates the proliferation of GBMs and the benefits of TMZ by coordinating the modification and degradation of RIG-I
Xiaowei Fei,Xiuquan Wu,Ya-nan Dou,Kai Sun,Qingdong Guo,Lei Zhang,Sanzhong Li,Jialiang Wei,Yu Huan,Xin-yu He,Zhou Fei +10 more
TL;DR: Tripartite motif 22 (TRIM22) is an agonist of nuclear factor κB (NF-κB) that plays an important role in the proliferation and drug sensitivity of glioblastoma (GBM) as discussed by the authors .
Treatment Strategy for Malignant Gliomas
TL;DR: It is revealed that the BBB’s objective is to provide a “smooth barrier” to protect against stroke-like injuries.